Additionally, cisplatin at sub-lethal doses appears to select a subset of cisplatin-resistant cells displaying a mesenchymal cell profile and expression of postulated osteosarcoma CSC markers (STRO-1/CD117), a phenotype that was reversed by γ-secretase inhibition. This evidence concerns the gene KIT and osteosarcoma.